You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Dow

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

Biologic Drugs With Dosage Form: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Details for Dosage Type: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Warsaw Orthopedic, Inc. (N/A) 2026-04-13 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Warsaw Orthopedic, Inc. (N/A) 2039-02-26 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Chelsea Therapeutics, Inc. (Charlotte, NC) 2024-09-08 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Hoffmann-La Roche Inc. (Nutley, NJ) 2027-05-02 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Aegis Therapeutics LLC (San Diego, CA) 2026-06-23 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Merck Sharp & Dohme Corp. (Rahway, NJ) 2030-05-11 RX search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21   Start Trial Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) 2030-11-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
Dow
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.